Patents by Inventor Nahid Ali

Nahid Ali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synergistic liposomal formulation for the treatment of cancer
    Patent number: 10426728
    Abstract: The present disclosure relates to the synergistic liposomal formulation comprising, phophatidylcholine, stearylamine and anticancer drugs for the treatment of cancer. The PC:SA cationic liposome encapsulated camptothecin (CPT) and doxorubicin (DOX) formulations show enhanced synergistic anti-cancer effect and provide improved therapeutic index as compared to either the liposome or drug alone. The present disclosure also relates to the use of Cationic liposomal preparation of phosphatidylcholine:stearylamine (PC:SA) showing anticancer effect. The SA-bearing liposome and drug entrapped in the liposome are effective against cancer both in vitro and in vivo, without causing any adverse effect on host.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: October 1, 2019
    Assignee: Council of Scientific and Industrial Research
    Inventors: Nahid Ali, Manjarika De, Triparna Sen
  • SYNERGISTIC LIPOSOMAL FORMULATION FOR THE TREATMENT OF CANCER
    Publication number: 20160228366
    Abstract: The present disclosure relates to the synergistic liposomal formulation comprising, phophatidylcholine, stearylamine and anticancer drugs for the treatment of cancer. The PC:SA cationic liposome encapsulated camptothecin (CPT) and doxorubicin (DOX) formulations show enhanced synergistic anti-cancer effect and provide improved therapeutic index as compared to either the liposome or drug alone. The present disclosure also relates to the use of Cationic liposomal preparation of phosphatidylcholine:stearylamine (PC:SA) showing anticancer effect. The SA-bearing liposome and drug entrapped in the liposome are effective against cancer both in vitro and in vivo, without causing any adverse effect on host.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 11, 2016
    Inventors: Nahid Ali, Manjarika De, Triparna Sen
  • Substituted cathechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma
    Patent number: 9302967
    Abstract: The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: April 5, 2016
    Assignee: Council of Scientific & Industrial Research
    Inventors: Santu Bandyopadhyay, Balaram Ghosh, Parasuraman Jaisankar, Bikas Chandra Pal, Siddhartha Roy, Bholanath Paul, Arjun Ram, Ulaganathan Mabalirajan, Nahid Ali, Arun Bandopadhyay, Aditya Konar, Jayashree Bagchi Chakraborty, Indrani Choudhury Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, Anirban Manna, Roma Sinha, Pradyot Bhattacharya, Jayaraman Vinayagam, Deba Prasad Jana, Sushovan Chowdhury
  • SUBSTITUTED CATHECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA
    Publication number: 20140135393
    Abstract: The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.
    Type: Application
    Filed: April 11, 2012
    Publication date: May 15, 2014
    Applicant: Council of Scientific & Industrial Research
    Inventors: Santu Bandyopadhyay, Balaram Ghosh, Parasuraman Jaisankar, Bikas Chandra Pal, Siddhartha Roy, Balaram Ghosh, Parasuraman Jaisankar, Bikas Pal, Nahid Ali, Siddhartha Roy, Bholanath Paul, Arjun Ram, Siddhartha Roy, Bholanath Paul, Arjun Ram, Ulaganathan Mabalirajan, Nahid Ali, Arun Bandopadhyay, Aditya Konar, Jayashree Bagchi Chakraborty, Indrani Chowdhury Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, Anirban Manna, Roma Sinha, Prayot Bhattacharya, Jayaraman Vinayagam, Deba Prasad Jana, Sushovan Chowdhury
  • Liposomal formulation and use thereof
    Publication number: 20120207821
    Abstract: Cationic liposome encapsulated antimonial drugs formulations are provided. The drug-loaded liposome have enhanced efficacy as antileismanial agents and provide improved therapeutic index as compared to the minimal dose of free drug.
    Type: Application
    Filed: April 17, 2012
    Publication date: August 16, 2012
    Inventors: Nahid Ali, Jayeeta Ghose, Swati P. Bhowmick
  • Liposomal formulation and use thereof
    Publication number: 20070026061
    Abstract: Cationic liposome encapsulated antimonial drugs formulations are provided. The drug-loaded liposome have enhanced efficacy as antileismanial agents and provide improved therapeutic index as compared to the minimal dose of free drug.
    Type: Application
    Filed: May 23, 2006
    Publication date: February 1, 2007
    Inventors: Nahid Ali, Jayeeta Ghose, Swati Bhowmick